Eris Q2 FY27: revenue up 12.6%, profit up 39.2%, margin recovery ahead

Mgmt Guided Margin ImprovementInvestor Communications View source PDF Explain this filing

ERIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.0%Reaction day

₹1089.60

prior close

₹1115.30

announcement price

In-mkt

timing

Nifty Microcap 250market+0.4%+0.6% vs market

Pharmaceuticals peers, median of 174sector+1.2%-0.3% vs sector

On the reaction day the stock moved 0.6 pts more than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.4

10m

-0.5

15m

-0.7

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.0+0.4+0.6+1.2-0.3

Next day

+9.1+2.1+7.0+3.1+6.0

+7.7pendingpending+4.7+3.0

—————

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 174Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Eris reported Q2 FY27 revenue of Rs 892 crore, up 12.6%, EBITDA of Rs 309 crore, up 7.3%, and profit after tax of Rs 187 crore, up 39.2%. Adjusted profit rose 17.5% to Rs 158 crore. Consolidated EBITDA margin fell to 34.7% from 36.4%. Management expects about 1 percentage point of gross-margin improvement excluding Zorvia, plus further gains from licensed brands.

Likely market impact

Revenue and profit growth is positive, but lower EBITDA margin tempers the outlook. Gross-margin gains ahead may aid profitability and cash flow.